Several kinase inhibitors of the PI3K-mTOR and MAPK signaling pathways are under different stages of clinical development, while others, like alpelisib (BYL-719) and trametinib, are already approved by the FDA to treat specific subgroups of cancer patients (36). The gene discussed is PIK3CA; the disease is cancer.